JP2004024054A - Fucoidan-based health food - Google Patents
Fucoidan-based health food Download PDFInfo
- Publication number
- JP2004024054A JP2004024054A JP2002182057A JP2002182057A JP2004024054A JP 2004024054 A JP2004024054 A JP 2004024054A JP 2002182057 A JP2002182057 A JP 2002182057A JP 2002182057 A JP2002182057 A JP 2002182057A JP 2004024054 A JP2004024054 A JP 2004024054A
- Authority
- JP
- Japan
- Prior art keywords
- fucoidan
- mixture
- wakame
- health food
- extracted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は、粉末状、カプセル、錠剤、あるいは、飲みやすくするために調味した溶液に溶解した水などの溶媒に溶解した飲み物として経口投与されるフコイダンを主体とした健康食品用に関する。
【0002】
【従来の技術】
従来から血糖値を下げ、ダイエット効果をもたらす健康食品として種々のものが知られており、とくに、フコイダン様多糖複合体が、変異細胞の除去により組織の癌化を防ぐナチュラルキラ−細胞(NK)活性の亢進と、進入異物等を除去し免疫成立の重要な一員であるマクロファ−ジ(Mφ)貧食能の亢進活性により、生体防御能賦活活性を向上させる機能を有することが知られており、特開2001−181303号には、ワカメの芽株部を冷間乾燥後、低温乾燥粉砕化することによって安価に提供する手法が開示されている。
【0003】
【発明が解決しようとする課題】
ところが、ワカメの芽株部から抽出されたフコダイン様多糖複合体自体は、生体防御亢進剤および免疫賦活性剤として優れた機能を有するものではあっても、他の健康食品用素材と混合した場合には、その機能が劣化する恐れがあり、付加添加物成分との競合劣化が起こる恐れがある。
また、このようなフコダイン様多糖複合体は、原料であるワカメの若芽独特の風味が強くなり過ぎて、健康食品としての味と風味に欠ける欠点もある。
【0004】
本発明の第1の課題は、ワカメの芽株部から抽出されたフコダイン様多糖複合体が有する生体防御亢進剤および免疫賦活性剤として優れた機能を、広く人間生活の健康維持に活かそうするもので、そのため、混合物として利用するための条件を見出すことにある。
【0005】
本発明の他の課題は、ワカメの芽株部から抽出したフコダイン様多糖複合体が有する生体防御亢進剤および免疫賦活性剤としての機能を低下せしめることのない添加物を見出すことである。
【0006】
また、他の課題は、ワカメの芽株部から抽出したフコダイン様多糖複合体の有する機能を強化し、あるいは、そのフコダイン様多糖複合体自体が有する機能を低下させることなく、新たな機能できる添加物を見出すことである。
【0007】
また、他の課題は、ワカメの芽株部から抽出したフコダイン様多糖複合体にその添加配合物を配合した混合物とした場合の、その機能が残存する最少含有量を確認することにある。
【0008】
さらには、ワカメの芽株部から抽出したフコダイン様多糖複合体を他の添加剤との混合物とした場合の、その機能が発揮できる含有量の上限値を確認することである。
【0009】
また、さらには、ワカメの芽株部から抽出したフコダイン様多糖複合体を飲食物として飲み易い状態とするための条件を確認することである。
【0010】
【課題を解決するための手段】
本発明は、ワカメ芽株より抽出分画したフコイダンは、沖縄フトモズクより抽出分画したフコイダンと特定量混合することによって、その機能は低減されることはなく、逆に増大し、さらに、ブラジル産のキノコであってβ−グルカンを含むアガリクス粉末を配合することによって健康食品として嘱望される機能が付加増大し、また、飲み易さの点でも優れたものとなるという知見の下で完成した。
【0011】
すなわち、沖縄フトモズクより抽出分画したフコイダンの特定量混合によって、ワカメ芽株より抽出分画したフコイダンの機能を低減することなく、沖縄フトモズクより抽出分画したフコイダンの機能が付加され、しかも、飲み易さが改善されたフコイダン系健康食品が得られる。
【0012】
ワカメ芽株より抽出分画したフコイダンが有する機能を強化するための添加配合物としては、ワカメ芽株より抽出分画したフコイダンの機能に抗癌機能を有すると云われているβ−グルカンを含むアガリクス(ブラジル原産 キノコ)粉末、ヒメマツタケ等のキノコの粉末が好適に使用でき、風味の点からも優れたものである。
【0013】
体重抑制効果と脂肪組織重量、血清中性脂質(トリグリセリド)、低密度リポタンパク、全コレステロール含量を軽減させるワカメ芽株フコイダンの機能は、同様の機能が期待される沖縄フトモズクフコイダンと、免疫能の亢進が期待されるアガリクスをそれぞれ特定割合配合することによって、それぞれの機能は些かも阻害されることはなく相互に相乗効果を発揮でき、変異細胞(異常、ガン化細胞)の除去を通じて組織のガン化を防ぐナチュラルキラ−細胞(NK)活性の亢進させる、即ち、生体防御能賦活活性を持つ。
【0014】
すなわち、本願発明のフコイダン系健康食品は、ワカメ芽株より抽出分画したフコイダン画分を1〜90%と残部が沖縄フトモズクより抽出分画したフコイダン画分からなる混合物にアガリクス粉末を配合した高血糖を抑制し、血糖を低く保つ効果を持つことを特徴とする。
【0015】
そのフコイダン系健康食品の好ましい配合組成は、ワカメ芽株より抽出分画したフコイダン画分が15〜35質量%と沖縄フトモズクより抽出分画したフコイダン画分が85〜65質量%からなる混合物に、混合物全量に対してアガリクス粉末を10〜20質量%混合したものである。
【0016】
ワカメ芽株より抽出分画したフコイダン(硫酸化多糖類)画分が、その機能をを発揮できるのは1%以上であり、また、90%以上では、原料であるワカメ芽株自体の風味が強すぎる。
【0017】
ワカメ芽株より抽出分画したフコイダンに添加配合する配合剤としては、一般のモズクから抽出したフコイダンが使用できるが、その中でも、沖縄フトモズクより抽出分画したフコイダンは、このワカメ芽株より抽出分画したフコイダンと比較して、その機能は低いが、類似の機能を発揮し、また、その風味は、ワカメ芽株より調製されたフコイダンより優れており、ワカメ芽株より抽出分画したフコイダンの配合物として最も適したものである。
【0018】
また、ワカメ芽株およびフトモズクとの混合物は、その特性が失われない範囲内で、他の海外産褐藻類からの抽出物と代替することができる。
【0019】
また、混合したアガリクスは、アガリクスと同様の機能があると云われているヒメマツタケと少量(10%程度まで)代替しても、本発明の健康食品の機能と風味が失われることはない。 したがって、本発明にいうアガリクスは、このような代替物と一部置換したものを総称する。
【0020】
本発明のフコイダン系健康食品は、体重抑制効果と脂肪組織重量、血清中性脂質(トリグリセリド)、低密度リポタンパク、全コレステロール含量を軽減させる効果のあるワカメ芽株フコイダン(硫酸化多糖類)を基材として、その機能を何等阻害させることなく、沖縄フトモズクフコイダンとアガリクス粉末の機能を付加し、さらには、それらの効果を相乗的に発揮させることができ、その上、ワカメ芽株フコイダンの飲み易さが改善される。
【0021】
また、本発明のフコイダン系健康食品は、元来は粉末状であり、粉末状あるいは錠剤として供せられるが、本質的には水溶性であるので、水あるいは調味した溶液等に溶かして通常のドリンクとしても、また、他の食材に混合して供することもできる。
【0022】
【発明の実施の形態】
以下、実施例によって本願発明の実施の形態を説明する。
【0023】
1. 配合原料の調製
ワカメ芽株より抽出分画したフコイダン画分
ワカメの芽株を採取後海水で洗浄し、次いで、一昼夜天日乾燥し低温乾燥した。水分含量は6.2±0.5%であった。次いで、乾燥された芽株を石臼で低温粉砕を行った。粒径は35〜170メッシュであった。この芽株粉体試料10kgを80%エタノ−ルで2回洗浄後、濾過した後、水を170l加えた後、85〜90℃まで加熱し水抽出を行った。次いで40〜50℃に冷却した後、プロテアーゼを少量加え4時間攪拌した。次いで、80〜90℃に加熱し水抽出と同時にプロテアーゼを失活させた。次いで、フィルターで濾過した後、噴露乾燥し、粗粉末フコイダン様多糖複合体を得た。
【0024】
沖縄フトモズクフコイダン画分
ワカメ芽株より抽出分画したフコイダン画分と同様に原料処理した粗粉末フコイダン様多糖複合体を使用した。
【0025】
アガリクス(学名 Agaricus Blajei Murrill)
種菌の産地はブラジルであって、種菌をバガス培地に摂取し、培養後、菌糸体を抽出エキス化し、粉末にしたものを使用した。
【0026】
2. 混合物の調製
上記ワカメ芽株より抽出分画したフコイダン画分が1〜90%の範囲内で沖縄フトモズクフコイダン画分とアガリクスとの混合粉末を種々ブレンドし、感応試験により違和感がなく飲むことができる配合混合物を得た。 その配合混合物は、ワカメ芽株より抽出分画したフコイダン画分が15〜35%と、沖縄フトモズクより抽出分画したフコイダン画分が85〜65%からなる混合物に、混合物全量に対してアガリクス粉末を10〜20%混合した。
【0027】
3. 混合物の効能試験
この感応試験によって最も飲み易い易い混合物は、効能において優れているワカメ芽株フコイダンが比較的少なく、沖縄フトモズクが多く配合されているために、果たして、その配合混合物がその生体防御亢進剤および免疫賦活性剤としての機能が発揮できるか、また、アガリクスによる付加機能による影響を実験用ラットに、本発明の配合物を2%配合した飼料として与えて、それによる抗肥満効果、血液性状への効果、血清コレステロール含量等への効果を実施例の分画区によって調べた。 比較のために、本発明の配合物を添加しない飼料の分画区を比較例とした。
表1は、この実験に使用した飼料の配合割合を示す。
【表1】
(1) 抗肥満効果
ラット(ウイスター、 雄、5週令)に30日間、実験飼料を投与し、体重変化、血液性状、脂肪組織重量への効果を調べた。 検討結果を図1に示す。 グラフ中のバ−は標準誤差を示す。同図に示すように、本発明のフコイダン系健康食品に係る配合粉末を投与したラットは、比較例に対して、体重は少なめに推移し、増体量も有意に少なくなった。
【0028】
(2) 血液性状への効果
ラットより血液を採取して血清を得、血清中の中性脂質について調べた。その結果を図2に示す。 同図の実施例と比較例との対比から、本発明のフコイダン系健康食品を含む飼料の投与は中性脂質(トリグリセリド)含量の減少に有効であることが分かる。
【0029】
(3) 血清コレステロール含量への効果
ラット血清中のコレステロール含量への影響について調べた。その結果を図3に示す。 同図に示すように、実施例と比較例との対比から、本発明のフコイダン系健康食品の投与によって総コレステロール含量は有意に減少した。
【0030】
(3) HDL−,LDL−コレステロール含量への効果
ラット血清中のHDL−,LDL−コレステロール含量について調べた。その結果を図4に示す。 同図に示すように、実施例と比較例との対比から、本発明のフコイダン系健康食品の投与によってHDL−コレステロール含量には影響を与えずに、生理的に悪役と言われ、肥満に関与するLDL−コレステロール量が有意に減少しており、血液性状の改善が見られ、健康保持上有益であることが認められた。
【0031】
(4) 脂肪組織重量への効果
同様にしてラットの脂肪組織重量を調べた。その結果を図5に示す。 使用した脂肪組織は腎臓周辺脂肪組織と副睾丸周辺脂肪組織である。同図に示すように、両脂肪組織重量とも実施例の場合が減少しており、本発明のフコイダン系健康食品の投与によって脂肪組織の減少に効果的であることが分かった。
【0032】
(5) ナチュラルキラ−活性への効果
ガン細胞を見つけて殺す機能を持つナチュラルキラ−活性を高めること、即ち生体防御能を亢進させることによって、ガンを予防、防止する可能性が考えられる。そこで、本発明のフコイダン系健康食品によるNK活性の亢進を検討した。
【0033】
▲1▼ NK細胞の調製
脾細胞の調製 : BALB/Cマウス(5週令、雄)に表1に示す本発明のフコイダン系健康食品を2%添加した飼料で20日間飼育し脾臓を得た。脾臓より細胞の浮遊液を得る。低張バッファーを加えて赤血球を溶血除去し、脾細胞を得た。これをRPMI培地でデッシュに入れ、37℃、5% 炭酸ガスで3時間培養して接着細胞を除き、NK細胞を含む脾リンパ球とした。
【0034】
▲2▼ YAC−1 細胞(リンパ腫細胞、ターゲット細胞)の調整
NK細胞(エフェクター細胞)のターゲットとなるYAC−1細胞(ターゲット細胞)を別途培養した。
【0035】
▲3▼ NK活性の測定
NK活性 の測定は、障害を受けた細胞の放出するLactate dehydrogenase(LDH) をマ−カ−とするる細胞障害性ELISA アッセイシステム(Cytotox96、Promega社) によった。以上の操作はて無菌的に行った。本発明のフコイダン系健康食品を20日間摂食したマウス脾臓のNK活性を図6に示す。 同図に示すように、本発明の実施例は、比較例に対して、高い傾向が見られ、本発明のフコイダン系健康食品がNK活性の亢進に有効であり、生体防御能を高めていることが認められた。
【0036】
▲4▼ 抗腫瘍活性
マウス (BALB/C、 雄、5週令)にサルコ−マ180腫瘍細胞を腰部皮下に投与し( 5×106細胞/マウス)、その後20日間、本発明のフコイダン系健康食品を添加した飼料を与えた。解体し、腰部皮下の腫瘍の重量を測定し、コントロール区と比較した。その結果を図7に示す。同図に示すように、投与区で明らかに腫瘍重量の減少が見られ、本発明のフコイダン系健康食品が腫瘍増殖抑制に有効であることが認められた。
【0037】
▲5▼ 担腫瘍マウスのナチュラルキラ−(NK)活性
上記の担腫瘍マウスの脾臓浮遊細胞中のNK活性の測定を行った。その測定結果を図8に示す。腫瘍細胞を皮下移植された担腫瘍マウスにおいても、本発明の配合物の投与によってNK活性は高い活性を示すことが認められ、これが腫瘍増殖抑制に機能しているものと結論づけられた。
【0038】
(6) 高血糖の抑制効果
インスリン非依存性糖尿病モデルマウス、KK−Ayマウス(5週令、雄、日本クレア)を70日間、表1の飼料を与えて飼育した。その間10日毎に尾より採血し、血糖値を測定した。その測定結果を図9に示す。血糖値の測定はグルコカード(Arkray、GT−1640、京都)を用いる酵素電極法によった。その結果、比較例のマウスの血糖値は飼育期間と共に上昇し、70日目には400mgグルコース/dl血清にも到達するが、実施例のマウスは約半分程度の200mg/dlの低い血糖値を維持し、本発明のフコイダン系健康食品は高血糖を強く抑制することを示した。
【0039】
【発明の効果】
本発明のフコイダン系健康食品は、ワカメ芽株フコイダン自体が有する体重抑制効果と脂肪組織重量、血清中性脂質(トリグリセリド)、低密度リポタンパク、全コレステロール含量を軽減させる効果を、沖縄フトモズクからのフコイダンを混合することによって増大し、さらには、アガリクスも有するといわれる制癌効果を増大することができる。
【0040】
また、本発明のフコイダン系健康食品は、その形態に関係なく人体に供与できる。
【図面の簡単な説明】
【図1】飼料を投与したときの1ヶ月間の体重変動を示す。
【図2】飼料を1ヶ月間摂食させたときのラット血清中の中性脂質含量の変化を示す。
【図3】飼料を1ヶ月間摂食させたときのラット血清中の総コレステロール含量の変化を示す。
【図4】飼料を1ヶ月間摂食させたときのラット血清中の低密度(LDL)コレステロールと高密度(HDL)コレステロール含量の変化を示す。
【図5】飼料を1ヶ月間摂食させたときのラットの脂肪組織重量の変化を示す。
【図6】飼料を20日間摂食させたときのマウス脾臓中のナチュラルキラ−活性の変化を示す。
【図7】サルコ−マ180を移植し、その後、本発明のフコイダン系健康食品を20日間摂食させたときのサルコ−マ180により生じた腫瘍重量の変化を示す。
【図8】サルコ−マ180を移植し、その後、本発明のフコイダン系健康食品を20日間摂食させたときのマウス脾臓中のナチュラルキラ−活性の変化を示す。
【図9】糖尿病モデルマウス、KK−Ayに飼料を70日間投与したときの血糖値の変化を示す。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a health food product mainly composed of fucoidan which is orally administered as a powder, a capsule, a tablet, or a drink dissolved in a solvent such as water dissolved in a solution seasoned for easy drinking.
[0002]
[Prior art]
BACKGROUND ART Various types of health foods have been conventionally known as health foods that lower blood sugar levels and bring about a diet effect. In particular, fucoidan-like polysaccharide complex is a natural killer cell (NK) that prevents canceration of tissues by removing mutant cells. It is known that it has a function of enhancing the biological defense ability activating activity by enhancing the activity and enhancing the macrophage (Mφ) poor phagocytic activity, which is an important member of immunization by removing invasion foreign substances and the like. Japanese Patent Application Laid-Open No. 2001-181303 discloses a method of providing a low-priced wakame bud by cold-drying and then pulverizing it at a low temperature.
[0003]
[Problems to be solved by the invention]
However, even if the fucodine-like polysaccharide complex extracted from the bud strain part of wakame itself has excellent functions as a biological defense enhancer and an immunostimulant, when it is mixed with other health food materials, Has a possibility that its function may be deteriorated, and there is a possibility that competitive deterioration with an additive component may occur.
In addition, such a fucodine-like polysaccharide complex also has a drawback that the flavor peculiar to the young buds of wakame, which is a raw material, becomes too strong and lacks the taste and flavor as a health food.
[0004]
A first object of the present invention is to make use of the excellent functions of a fucodyne-like polysaccharide complex extracted from a bud strain of wakame as a biological defense enhancer and an immunostimulatory agent for maintaining health of human life widely. Therefore, an object of the present invention is to find conditions for use as a mixture.
[0005]
Another object of the present invention is to find an additive which does not decrease the functions of the fucodine-like polysaccharide complex extracted from the bud strain of seaweed as a biological defense enhancer and an immunostimulant.
[0006]
Another object is to enhance the function of the fucodyne-like polysaccharide complex extracted from the bud strain of wakame, or to add a new function without reducing the function of the fucodyne-like polysaccharide complex itself. Finding things.
[0007]
Another object of the present invention is to confirm the minimum content of the mixture obtained by blending the fucodyne-like polysaccharide complex extracted from the bud portion of wakame with the additive compound and remaining its function.
[0008]
Another object of the present invention is to confirm the upper limit of the content in which the function can be exhibited when the fucodine-like polysaccharide complex extracted from the bud strain of wakame is mixed with other additives.
[0009]
It is still another object of the present invention to confirm conditions for preparing a fucodyne-like polysaccharide complex extracted from a bud strain of wakame as a food or drink.
[0010]
[Means for Solving the Problems]
According to the present invention, the function of fucoidan extracted and fractionated from the seaweed bud strain is not reduced, but is increased, by mixing a specific amount of fucoidan extracted and fractionated from Okinawa Fumozuku, and furthermore, it is produced in Brazil. It has been completed under the finding that the addition of agaricus powder containing β-glucan increases the functions expected as health foods and also improves the ease of drinking.
[0011]
That is, by mixing a specific amount of fucoidan extracted and fractionated from Okinawa Futomozuku, without reducing the function of fucoidan extracted and fractionated from Wakame bud strain, the function of fucoidan extracted and fractionated from Okinawa Futomozuku is added, and A fucoidan-based health food with improved ease can be obtained.
[0012]
Additives for enhancing the function of fucoidan extracted and fractionated from wakame sprouts include β-glucan, which is said to have an anticancer function in the function of fucoidan extracted and fractionated from wakame sprouts. Agaricus (mushrooms native to Brazil) powder and mushroom powders such as Himematsutake can be suitably used, and are excellent in flavor.
[0013]
Fucoidan, a wakame bud strain that reduces body weight, adipose tissue weight, serum neutral lipids (triglycerides), low-density lipoprotein, and total cholesterol, is expected to have similar functions. By adding a specific proportion of Agaricus, which is expected to increase its function, each function can exert synergistic effects with each other without any slight inhibition, and the removal of mutant cells (abnormal, cancerous cells) It enhances natural killer cell (NK) activity that prevents canceration, that is, has a biological defense ability activating activity.
[0014]
That is, the fucoidan-based health food of the present invention is a hyperglycemia obtained by mixing agaricus powder with a mixture of 1 to 90% of a fucoidan fraction extracted and fractionated from a seaweed bud strain and the remainder being a fucoidan fraction extracted and fractionated from Okinawa Fumozuku. And has the effect of keeping blood sugar low.
[0015]
A preferred composition of the fucoidan-based health food is a mixture comprising 15 to 35% by mass of the fucoidan fraction extracted and fractionated from the wakame bud strain and 85 to 65% by mass of the fucoidan fraction extracted and fractionated from Okinawa Futomozuku. Agarix powder is mixed in an amount of 10 to 20% by mass with respect to the total amount of the mixture.
[0016]
The fucoidan (sulfated polysaccharide) fraction extracted and fractionated from the wakame bud strain can exert its function at 1% or more, and at 90% or more, the flavor of the wakame bud strain itself as a raw material is reduced. too strong.
[0017]
The fucoidan extracted and extracted from the wakame bud strain can be used as a combination agent, and fucoidan extracted from general mozuku can be used. Among them, fucoidan extracted and fractionated from Okinawa Fumozuku is extracted from this wakame bud strain. Compared to the fucoidan fractionated, it has a lower function, but exhibits a similar function, and its flavor is superior to fucoidan prepared from the wakame bud strain, and the fucoidan extracted and fractionated from the wakame bud strain Most suitable as a formulation.
[0018]
In addition, the mixture with the wakame bud strain and the moss can be replaced with an extract from another overseas brown algae as long as the characteristics are not lost.
[0019]
Even if the mixed agaricus is replaced with a small amount (up to about 10%) of Himematsutake, which is said to have the same function as the agaricus, the function and flavor of the health food of the present invention are not lost. Therefore, the term "agaricus" in the present invention is a generic term for those partially substituted with such substitutes.
[0020]
The fucoidan-based health food of the present invention comprises a wakame bud strain fucoidan (sulfated polysaccharide) having an effect of reducing body weight, adipose tissue weight, serum neutral lipid (triglyceride), low-density lipoprotein, and total cholesterol content. As a base material, without impairing its function at all, we can add the functions of Okinawa Fumozuku fucoidan and Agaricus powder, and furthermore, can exert their effects synergistically. Drinkability is improved.
[0021]
Further, the fucoidan-based health food of the present invention is originally in the form of a powder, and is provided as a powder or a tablet.However, since it is essentially water-soluble, it can be dissolved in water or a seasoned solution or the like to obtain a normal food. It can be served as a drink or mixed with other ingredients.
[0022]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, embodiments of the present invention will be described with reference to examples.
[0023]
1. Preparation of compounding raw material The fucoidan fraction extracted from the wakame sprouts strain, the wakame sprouts strain was collected and washed with seawater, then dried all day and night and dried at low temperature. The water content was 6.2 ± 0.5%. Next, the dried bud strain was subjected to low-temperature pulverization with a stone mill. The particle size was 35-170 mesh. After washing 10 kg of the sprouts powder sample twice with 80% ethanol, filtration was performed, 170 l of water was added, and the mixture was heated to 85 to 90 ° C. to perform water extraction. Then, after cooling to 40 to 50 ° C, a small amount of protease was added and the mixture was stirred for 4 hours. Then, the protease was heated to 80 to 90 ° C. to inactivate the protease simultaneously with the water extraction. Next, the mixture was filtered with a filter and then dried by blowing to obtain a crude powdery fucoidan-like polysaccharide complex.
[0024]
Crude powder fucoidan-like polysaccharide complex treated as a raw material in the same manner as the fucoidan fraction extracted and fractionated from the wakame bud strain of Okinawa mushroom fucoidan fraction was used.
[0025]
Agaricus (scientific name: Agaricus Blajei Murrill)
The inoculum is produced in Brazil. The inoculum was taken into bagasse medium, and after culturing, the mycelium was extracted and powdered.
[0026]
2. Preparation of Mixture The fucoidan fraction extracted and fractionated from the wakame bud strain is mixed with various powders of Okinawa Fumozuku fucoidan fraction and Agaricus within a range of 1 to 90%, and can be drunk without any discomfort by a sensitivity test. A possible blended mixture was obtained. The blended mixture was a mixture comprising 15-35% of a fucoidan fraction extracted and fractionated from the wakame bud strain and 85-65% of a fucoidan fraction extracted and fractionated from Okinawa Fumozuku, and Agaricus powder based on the total amount of the mixture. Was mixed at 10-20%.
[0027]
3. Efficacy test of the mixture The mixture that is the easiest to drink according to this sensitivity test is relatively low in wakame bud strain fucoidan, which is excellent in efficacy, and contains a large amount of Okinawa Futomozuku. Of the present invention as a feed containing 2% of the composition of the present invention to an experimental rat as to whether it can exhibit its function as an agent and an immunostimulant, and the effect of the additional function of agaricus, thereby giving an anti-obesity effect, blood The effects on properties, serum cholesterol content, and the like were examined using the fractions of Examples. For comparison, a fraction fraction of feed without the formulation of the present invention was used as a comparative example.
Table 1 shows the mixing ratio of the feed used in this experiment.
[Table 1]
(1) Anti-obesity effect Rats (Wistar, male, 5 weeks old) were administered with an experimental diet for 30 days, and the effects on body weight change, blood properties and adipose tissue weight were examined. FIG. 1 shows the examination results. The bar in the graph indicates the standard error. As shown in the figure, in the rats to which the compound powder according to the fucoidan-based health food of the present invention was administered, the weight of the rats was lower than that of the comparative example, and the amount of gain was significantly reduced.
[0028]
(2) Effects on blood properties Blood was collected from rats to obtain serum, and neutral lipids in the serum were examined. The result is shown in FIG. From the comparison between the example of the figure and the comparative example, it can be seen that administration of a feed containing the fucoidan-based health food of the present invention is effective in reducing the content of neutral lipids (triglycerides).
[0029]
(3) Effect on serum cholesterol content The effect on serum cholesterol content in rat serum was examined. The result is shown in FIG. As shown in the figure, from the comparison between the examples and the comparative examples, the administration of the fucoidan-based health food of the present invention significantly reduced the total cholesterol content.
[0030]
(3) Effect on HDL-, LDL-cholesterol content The HDL-, LDL-cholesterol content in rat serum was examined. The result is shown in FIG. As shown in the figure, from the comparison between Examples and Comparative Examples, administration of the fucoidan-based health food of the present invention did not affect the HDL-cholesterol content, but was said to be physiologically villain and involved in obesity. LDL-cholesterol level significantly decreased, blood properties were improved, and it was recognized that it was beneficial for health maintenance.
[0031]
(4) Effect on Adipose Tissue Weight Rat adipose tissue weight was examined in the same manner. The result is shown in FIG. The adipose tissue used was adipose tissue around the kidney and adipose tissue around the epididymis. As shown in the figure, the weight of both adipose tissues was reduced in the case of Example, and it was found that administration of the fucoidan-based health food of the present invention was effective in reducing adipose tissue.
[0032]
(5) Effect on Natural Killer Activity There is a possibility that cancer may be prevented or prevented by enhancing natural killer activity having a function of finding and killing cancer cells, that is, enhancing biological defense ability. Then, the enhancement of NK activity by the fucoidan health food of the present invention was examined.
[0033]
{Circle around (1)} Preparation of NK cells Preparation of spleen cells: BALB / C mice (5 weeks old, male) were bred for 20 days with a diet containing 2% of the fucoidan-based health food of the present invention shown in Table 1 to obtain spleens. . Obtain cell suspension from spleen. Red blood cells were hemolyzed and removed by adding a hypotonic buffer to obtain splenocytes. This was placed in a dish with an RPMI medium, and cultured at 37 ° C. for 3 hours in 5% carbon dioxide to remove adherent cells to obtain splenic lymphocytes containing NK cells.
[0034]
{Circle around (2)} Preparation of YAC-1 cells (lymphoma cells, target cells) YAC-1 cells (target cells) serving as targets of NK cells (effector cells) were separately cultured.
[0035]
(3) Measurement of NK activity The NK activity was measured by a cytotoxicity ELISA assay system (Cytox96, Promega) using Lactate dehydrogenase (LDH) released by the damaged cells as a marker. The above operation was performed aseptically. FIG. 6 shows the NK activity of the spleen of a mouse fed with the fucoidan health food of the present invention for 20 days. As shown in the figure, the examples of the present invention show a higher tendency than the comparative examples, and the fucoidan-based health food of the present invention is effective for enhancing NK activity and enhancing the biological defense ability. It was recognized that.
[0036]
(4) Antitumor activity mice (BALB / C, male, 5 weeks old) were injected with sarcoma 180 tumor cells subcutaneously in the lumbar region (5 × 10 6 cells / mouse), and then for 20 days, the fucoidan health of the present invention was administered. Food was added to the food. After disassembly, the weight of the tumor under the lumbar region was measured and compared with the control group. FIG. 7 shows the result. As shown in the figure, the weight of the tumor was clearly reduced in the administration group, and it was confirmed that the fucoidan-based health food of the present invention was effective in suppressing tumor growth.
[0037]
(5) Natural killer (NK) activity of tumor-bearing mice NK activity in the spleen floating cells of the tumor-bearing mice was measured. FIG. 8 shows the measurement results. Even in tumor-bearing mice into which tumor cells were subcutaneously transplanted, it was confirmed that the administration of the composition of the present invention showed high NK activity, and it was concluded that this functioned to suppress tumor growth.
[0038]
(6) Suppressive Effect of Hyperglycemia Non-insulin-dependent diabetes model mice and KK-Ay mice (5-week-old, male, CLEA Japan) were bred for 70 days with the feed shown in Table 1. During that time, blood was collected from the tail every 10 days, and the blood glucose level was measured. FIG. 9 shows the measurement results. The measurement of the blood glucose level was performed by an enzyme electrode method using a glucocard (Arkray, GT-1640, Kyoto). As a result, the blood glucose level of the mouse of the comparative example increased with the breeding period, and reached as high as 400 mg glucose / dl serum on the 70th day. Maintained, it was shown that the fucoidan health food of the present invention strongly inhibits hyperglycemia.
[0039]
【The invention's effect】
The fucoidan-based health food of the present invention has an effect of reducing body weight suppressing effect and adipose tissue weight, serum neutral lipid (triglyceride), low-density lipoprotein, and total cholesterol content of seaweed bud strain fucoidan itself, from Okinawa Fumozuku. It can be increased by mixing fucoidan and further increase the anti-cancer effect said to also have agaricus.
[0040]
Further, the fucoidan health food of the present invention can be provided to a human body regardless of its form.
[Brief description of the drawings]
FIG. 1 shows the change in body weight during one month when a feed was administered.
FIG. 2 shows changes in the neutral lipid content in rat serum when the feed is fed for one month.
FIG. 3 shows changes in the total cholesterol content in rat serum when the feed is fed for one month.
FIG. 4 shows changes in low-density (LDL) cholesterol and high-density (HDL) cholesterol content in rat serum when the diet is fed for one month.
FIG. 5 shows a change in adipose tissue weight of a rat when the feed was fed for one month.
FIG. 6 shows changes in natural killer activity in spleens of mice when the feed was fed for 20 days.
FIG. 7 shows the change in tumor weight caused by sarcoma 180 when sarcoma 180 is transplanted and then fed with a fucoidan-based health food of the present invention for 20 days.
FIG. 8 shows changes in natural killer activity in mouse spleen when sarcoma 180 was transplanted and then fed with a fucoidan-based health food of the present invention for 20 days.
FIG. 9 shows a change in blood glucose level when a diet is administered to a diabetes model mouse, KK-Ay, for 70 days.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002182057A JP2004024054A (en) | 2002-06-21 | 2002-06-21 | Fucoidan-based health food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002182057A JP2004024054A (en) | 2002-06-21 | 2002-06-21 | Fucoidan-based health food |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2004024054A true JP2004024054A (en) | 2004-01-29 |
Family
ID=31178720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002182057A Pending JP2004024054A (en) | 2002-06-21 | 2002-06-21 | Fucoidan-based health food |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2004024054A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005225924A (en) * | 2004-02-10 | 2005-08-25 | Tohoku Yoshioka:Kk | Method for producing fucoidan extract, fucoidan extract and food |
WO2007013613A1 (en) * | 2005-07-29 | 2007-02-01 | Suntory Limited | Composition containing fucoidan or fucoidan hydrolysate and immunopotentiating material |
JP2007153880A (en) * | 2005-11-09 | 2007-06-21 | Nippon Seiyaku Kogyo Kk | Food and drink and anti-tumor agent |
WO2008018138A1 (en) | 2006-08-10 | 2008-02-14 | Wood One Co., Ltd. | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia |
WO2008041799A1 (en) * | 2006-10-02 | 2008-04-10 | Bion Co., Ltd | Bioavailable fucoidan and methods for preparing the same |
WO2010081259A1 (en) * | 2009-01-19 | 2010-07-22 | 北京绿色金可生物技术股份有限公司 | A composition comprising extraction of fucoxanthin |
JP2011184305A (en) * | 2010-03-04 | 2011-09-22 | Kyosei Seiyaku Kk | Adiponectin production promoter |
US8124137B2 (en) | 2006-08-10 | 2012-02-28 | Mimozax Co., Ltd. | Composition for prevention and/or treatment of tumors containing acacia bark derivative |
US8124138B2 (en) | 2006-08-10 | 2012-02-28 | Mimozax Co., Ltd. | Composition for prevention and/or treatment of pruritus containing acacia bark derivative |
US8673287B2 (en) | 2006-08-10 | 2014-03-18 | Mimozax Co., Ltd. | Anti-obesity composition containing acacia bark derivative |
US9132159B2 (en) | 2006-08-10 | 2015-09-15 | Mimozax Co., Ltd. | Composition for prevention and/or treatment of tumors containing acacia derivative |
JP2016042804A (en) * | 2014-08-20 | 2016-04-04 | 株式会社ヴェントゥーノ | Fucoidan health food |
-
2002
- 2002-06-21 JP JP2002182057A patent/JP2004024054A/en active Pending
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4599571B2 (en) * | 2004-02-10 | 2010-12-15 | 株式会社東北ヨシオカ | Fucoidan extract manufacturing method |
JP2005225924A (en) * | 2004-02-10 | 2005-08-25 | Tohoku Yoshioka:Kk | Method for producing fucoidan extract, fucoidan extract and food |
WO2007013613A1 (en) * | 2005-07-29 | 2007-02-01 | Suntory Limited | Composition containing fucoidan or fucoidan hydrolysate and immunopotentiating material |
JP2007153880A (en) * | 2005-11-09 | 2007-06-21 | Nippon Seiyaku Kogyo Kk | Food and drink and anti-tumor agent |
WO2008018138A1 (en) | 2006-08-10 | 2008-02-14 | Wood One Co., Ltd. | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia |
US8124137B2 (en) | 2006-08-10 | 2012-02-28 | Mimozax Co., Ltd. | Composition for prevention and/or treatment of tumors containing acacia bark derivative |
US8124138B2 (en) | 2006-08-10 | 2012-02-28 | Mimozax Co., Ltd. | Composition for prevention and/or treatment of pruritus containing acacia bark derivative |
US8128969B2 (en) | 2006-08-10 | 2012-03-06 | Mimozax Co., Ltd. | Hypoglycemic composition containing acacia bark derivative |
US8673287B2 (en) | 2006-08-10 | 2014-03-18 | Mimozax Co., Ltd. | Anti-obesity composition containing acacia bark derivative |
US9132159B2 (en) | 2006-08-10 | 2015-09-15 | Mimozax Co., Ltd. | Composition for prevention and/or treatment of tumors containing acacia derivative |
WO2008041799A1 (en) * | 2006-10-02 | 2008-04-10 | Bion Co., Ltd | Bioavailable fucoidan and methods for preparing the same |
WO2010081259A1 (en) * | 2009-01-19 | 2010-07-22 | 北京绿色金可生物技术股份有限公司 | A composition comprising extraction of fucoxanthin |
US8454970B2 (en) | 2009-01-19 | 2013-06-04 | Beijing Gingko Group Biological Technology Co., Ltd. | Compositions containing fucoxanthin extract |
JP2011184305A (en) * | 2010-03-04 | 2011-09-22 | Kyosei Seiyaku Kk | Adiponectin production promoter |
JP2016042804A (en) * | 2014-08-20 | 2016-04-04 | 株式会社ヴェントゥーノ | Fucoidan health food |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050129708A1 (en) | Fucoidan-based health food | |
JP2004024054A (en) | Fucoidan-based health food | |
JPS6140763A (en) | Antiobesity food | |
US8722614B2 (en) | Adiponectin production enhancer | |
KR20170099539A (en) | Sedum composition promoting antioxidant and alcohol oxidation | |
JP6042800B2 (en) | Tomatoside A extraction method | |
CN1791400A (en) | Composition for lowering lipid in body | |
TWI277422B (en) | Turmeric-containing composition | |
JPH09278662A (en) | Antiallergic agent | |
EP1413208A1 (en) | Health food and antitumor agent | |
KR101742266B1 (en) | Composition for improving hepatic, stomachic function and curing hangover | |
CN103859403A (en) | Food prepared by quick-oil-boiling amorphophallus konjac with phytosterol oil and preparation method of food | |
JP2003342188A (en) | Anticancer agent | |
JPWO2006008890A1 (en) | Muscle building composition | |
JP6016610B2 (en) | Supplements for muscle gain | |
TW201716066A (en) | Composition for inhibiting alcohol absorption | |
KR101073624B1 (en) | Compositions comprising young Phragmites communis leaves or extracts thereof for preventing or improving obesity, or antioxidant activity | |
KR101189141B1 (en) | Method for preparing fiber of Aloe vera Linne parenchyma tissue for the dietary fiber | |
KR100786363B1 (en) | Concentration of Natural Complex Useful for the Control of Hypercholesterolemia and Obesity and Preparation Thereof | |
KR101166852B1 (en) | Compositions comprising Hippophae rhamnoides L. leaves or extracts thereof for amelioration of body lipid | |
JP3431577B2 (en) | Pharmaceutical composition | |
JP2003231641A (en) | Pharmaceutical composition for prevention or treatment of hepatic function disorder | |
JP2001103927A (en) | Method of producing agaricus blazei murill extract having high antitumor activity | |
KR101929388B1 (en) | Composition for prevention, treatment or improvement of liver disease comprising italian ryegrass extraction fraction as an active ingredient | |
JP3493585B2 (en) | Blood pressure lowering and serum triglyceride lowering agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041210 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060915 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061114 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070119 |